ArticleFrontiers in pharmacology2025
Prediction of adverse drug reactions based on pharmacogenomics combination features: a preliminary study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Informative relational learning for adverse reaction prediction with enhanced generalization to novel drugs.Bioinformatics (Oxford, England) · 2026Article
- Early prediction and risk assessment of adverse drug combinations using ensemble learning.Scientific reports · 2026Article
- Bronchiectasis in the precision medicine era: pathogenesis and therapeutic advances.Journal of thoracic disease · 2026Review
- Vardenafil in the multidisciplinary management of erectile dysfunction: a narrative review on multidimensional outcomes and clinical integration.World journal of urology · 2026Review
- Pharmacogenomics testing to optimize medical countermeasures against chemical warfare agents and bacterial biothreats in military settings.Journal of military, veteran and family health · 2026Article
- Artificial Intelligence for Drug Safety Across the Lifecycle and Decision Type: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The critical need to implement pharmacogenomics in public health services: Mexico in the global picture.Frontiers in public health · 2026Article
- Multi-modal AI in precision medicine: integrating genomics, imaging, and EHR data for clinical insights.Frontiers in artificial intelligence · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Adverse Drug Reactions (ADRs), a widespread phenomenon in clinical drug treatment, are often associated with a high risk of morbidity and even death. Drugs and changes in gene expression are the two important factors that affect whether and how adverse reactions occur. Notably, pharmacogenomics data have recently become more available and could be used to predict ADR occurrence. However, there is a challenge in effectively analyzing the massive data lacking guidance on mutual relationship for ADRs prediction. Methods: We constructed separate similarity features for drugs and ADRs using pharmacogenomics data from the Comparative Toxicogenomics Database [CTD, including Chemical-Gene Interactions (CGIs) and Gene-Disease Associations (GDAs)]. We proposed a novel deep learning architecture, DGANet, based on the constructed features for ADR prediction. The algorithm uses Convolutional Neural Networks (CNN) and cross-features to learn the latent drug-gene-ADR associations for ADRs prediction. Results and Discussion: The performance of DGANet was compared to three state-of-the-art algorithms with different genomic features. According to the results, GDANet outperformed the benchmark algorithms (AUROC = 92.76%, AUPRC = 92.49%), demonstrating a 3.36% AUROC and 4.05% accuracy improvement over the cutting-edge algorithms. We further proposed new genomic features that improved DGANet's predictive capability. Moreover, case studies on top-ranked candidates confirmed DGANet's ability to predict new ADRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.